- Home
- BDX vs SKYD Comparison
BDX vs SKYD Comparison
Compare BDX & SKYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$215.59
N/A
Current Price
$7.60
Company Overview
Basic Information| Metric | BDX | SKYD |
|---|---|---|
| Founded | 1897 | 1914 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6B | 46.8B |
| IPO Year | 1999 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BDX | SKYD |
|---|---|---|
| Price | $215.59 | $7.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 24 |
| Target Price | ★ $226.14 | $9.06 |
| AVG Volume (30 Days) | 1.8M | ★ 25.1M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | 1.98% | ★ 2.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.59 | 0.25 |
| Revenue | $21,840,000,000.00 | ★ $29,213,000,000.00 |
| Revenue This Year | $1.74 | $127.80 |
| Revenue Next Year | $4.24 | $4.89 |
| P/E Ratio | $134.67 | ★ $31.50 |
| Revenue Growth | ★ 8.24 | N/A |
| 52 Week Low | $140.11 | $6.61 |
| 52 Week High | $216.74 | $9.48 |
Technical Indicators
Market Signals| Indicator | BDX | SKYD |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 39.24 |
| Support Level | $175.60 | $7.27 |
| Resistance Level | N/A | $8.59 |
| Average True Range (ATR) | 4.59 | 0.40 |
| MACD | 1.13 | 0.04 |
| Stochastic Oscillator | 93.02 | 26.80 |
Price Performance
Historical Comparison BDX
SKYD
About BDX Becton Dickinson and Company
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.